Market Barriers to the Development of Pharmacotherapies for the Treatment of Cocaine Abuse and Addiction: Final Report. Drug Marketing Issues


Two market barriers related to drug marketing were identified. As previously described, the possibility of the pharmacotherapy being distributed through publicly-funded treatment centers rather than through physician offices was a concern of the pharmaceutical companies because of the companies' limited access to patients.

Variations in federal, state and local regulations have proven to be market barriers in the case of LAAM. LAAM is the most highly regulated of the drugs (DEA Schedule 2), whereas Nicorette is the least regulated (available over-the-counter). DEA regulation of LAAM has limited market penetration by restricting delivery of LAAM to methadone maintenance clinics. In contrast, with its far less stringent regulation, Nicorette is readily available to its large target population.